Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

PRODIGE 62-OESIRI trial showed low efficacy of paclitaxel and 5FU Nal-IRI in the 2nd line treatment of mESCC, though paclitaxel provided a better safety profile. Trial registration NCT03719924.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-08-22
DOI
https://doi.org/10.1016/j.ejca.2025.115741
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

V. Ly Lebrun, Côme Lepage, David Tougeron, Vincent Hautefeuille et al.
European Journal of Cancer
Esophageal Cancer Research and Treatment
article

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

V. Ly Lebrun, Côme Lepage, David Tougeron, Vincent Hautefeuille, F. Khemissa Akouz, Laurent Mineur, V. Jestin Le Tallec, Astrid Lièvre, Olivier Bouché, J. Martin-Babau, Olivier Dubreuil, Thierry Lecomte, Aziz Zaanan, Frédéric Di Fiore, Aurélie Fadin, Vincent Bourgeois, Catherine Poisson Ligeza, Elsa Thimonier
article en

Abstract

PRODIGE 62-OESIRI trial showed low efficacy of paclitaxel and 5FU Nal-IRI in the 2nd line treatment of mESCC, though paclitaxel provided a better safety profile. Trial registration NCT03719924.

European Journal of CancerVol. 228
Université de Tours (FR), Inserm (FR), Institut Pasteur (FR), Université Paris Cité (FR), Hôpital Beaujon (FR), Université Rennes 2 (FR), Université de Poitiers (FR), Centre Hospitalier de Perpignan (FR), Oncogenesis Stress Signaling (FR), Centre Hospitalier Universitaire Amiens-Picardie (FR), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), Centre Hospitalier Universitaire de Reims (FR), Normandie Université (FR), Centre Hospitalier Universitaire de Poitiers (FR), Groupe Hospitalier Diaconesses Croix Saint-Simon (FR), Fédération Francophone de Cancérologie Digestive (FR), Centre Hospitalier Annecy Genevois (FR), Tennessee Oncology (US), Université d'été de Boulogne-sur-Mer (FR), Centre Hospitalier Universitaire de Rennes (FR), Institut Sainte Catherine (FR), Centre Hospitalier Saint-Nazaire (FR), Université de Rennes (FR), Université de Rouen Normandie (FR), Université de Limoges (FR), Université de Reims Champagne-Ardenne (FR)
Unicancer
Openalex Percentile: Top 65%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.